Mikhailov Alexander T, Torrado Mario
Institute of Health Sciences, University of La Coruña, 15006, La Coruña, Spain.
Heart Fail Rev. 2016 Nov;21(6):783-794. doi: 10.1007/s10741-016-9569-0.
There are multiple intrinsic mechanisms for diastolic dysfunction ranging from molecular to structural derangements in ventricular myocardium. The molecular mechanisms regulating the progression from normal diastolic function to severe dysfunction still remain poorly understood. Recent studies suggest a potentially important role of core cardio-enriched transcription factors (TFs) in the control of cardiac diastolic function in health and disease through their ability to regulate the expression of target genes involved in the process of adaptive and maladaptive cardiac remodeling. The current relevant findings on the role of a variety of such TFs (TBX5, GATA-4/6, SRF, MYOCD, NRF2, and PITX2) in cardiac diastolic dysfunction and failure are updated, emphasizing their potential as promising targets for novel treatment strategies. In turn, the new animal models described here will be key tools in determining the underlying molecular mechanisms of disease. Since diastolic dysfunction is regulated by various TFs, which are also involved in cross talk with each other, there is a need for more in-depth research from a biomedical perspective in order to establish efficient therapeutic strategies.
舒张功能障碍存在多种内在机制,范围从心室心肌的分子紊乱到结构紊乱。调节从正常舒张功能到严重功能障碍进展的分子机制仍知之甚少。最近的研究表明,核心心脏富集转录因子(TFs)通过调节参与适应性和适应性不良心脏重塑过程的靶基因表达,在健康和疾病状态下的心脏舒张功能控制中可能发挥重要作用。本文更新了关于多种此类TFs(TBX5、GATA-4/6、SRF、MYOCD、NRF2和PITX2)在心脏舒张功能障碍和衰竭中作用的相关研究结果,强调了它们作为新型治疗策略潜在靶点的可能性。反过来,这里描述的新动物模型将成为确定疾病潜在分子机制的关键工具。由于舒张功能障碍受多种TFs调节,且这些TFs之间也存在相互作用,因此需要从生物医学角度进行更深入的研究,以建立有效的治疗策略。